Precigen Announces First Patient Dosed For PRGN-2012 AdenoVerse Immunotherapy In Patients With Recurrent Respiratory Papillomatosis
Precigen Announces First Patient Dosed For PRGN-2012 AdenoVerse Immunotherapy In Patients With Recurrent Respiratory Papillomatosis
Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase I study of PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (RRP) (clinical trial identifier: NCT04724980). The US Food and Drug Administration recently granted Orphan Drug Designation for PRGN-2012 in RRP in March 2021.
Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase I study of PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (RRP) (clinical trial identifier: NCT04724980). The US Food and Drug Administration recently granted Orphan Drug Designation for PRGN-2012 in RRP in March 2021.
致力於開發創新的基因和細胞療法以改善患者生活的生物製藥公司Precigen,Inc.今天宣佈,PRGN-2012年的第一階段研究已經給第一名患者服用了劑量,這是一種針對成人複發性呼吸道乳頭狀瘤病患者的一流的研究現成的AdenoVerse™免疫療法(臨牀試驗標識符:NCT04724980)。美國食品和藥物管理局最近批准RRP中PRGN-2012的孤兒藥物命名2021年3月。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧